ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Cumberland Pharmaceuticals Inc. (CPIX) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Cumberland Pharmaceuticals Inc. (CPIX)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Pharmaceuticals
Competitors: MNK, RDY, AVNR, ANIP

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: B down upgrade
Last Week: C same downgrade
Two Weeks Ago: B up upgrade
service keys

Cumberland Pharmaceuticals Inc.© quotemedia

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. The company’s principal products include Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. It is also developing Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Recent News: Cumberland Pharmaceuticals Inc.